drugset / Trial / NCT03884751
Chimeric Antigen Receptor T Cells Targeting Glypican-3
Phase 1
Completed
9 enrolled
CARsgen Therapeutics Co., Ltd.
First Affiliated Hospital of Zhejiang University · collabNanJing PLA 81 Hospital · collabRenJi Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients with Advanced Hepatocellular Carcinoma
Timeline
- Start
- 2019-08-15
- Primary completion
- 2021-05-28
- Completion
- 2021-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-GPC3 T Cells | Cell therapy | — | Intravenous |